Recent Updates
Recently added Catalysts
ADMA Negative Sentiment Score: 25/100

ADMA INVESTIGATION: ADMA Biologics Investors with Losses are Notified to Contact BFA Law about Ongoing Securities Fraud Investigation into Auditor Resignation (Nasdaq:ADMA)

Key Takeaway: Bleichmar Fonti & Auld LLP has announced an investigation into ADMA Biologics for possible violations of federal securities laws following the resignation of its auditor, CohnReznick LLP. This unexpected resignation has caused ADMA Biologics' stock to fall over 20%. Investors are urged to seek legal guidance as they may have options available due to this situation. The investigation comes at a time when ADMA is already under scrutiny, raising concerns among shareholders.

Market Sentiment Analysis

CONCERNS & RISKS

  • ADMA Biologics faced a significant stock drop of over 20% following the unexpected resignation of its auditor.
  • The company is now under investigation for potential violations of federal securities laws.
  • Investors may experience financial losses as a result of these developments.

Full Press Release Details

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws.
If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc.
Why Did ADMA Biologics’s Stock Drop?
ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, markets and develops specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases.
On October 9, 2024, ADMA Biologics disclosed the surprise resignation of its independent outside auditor CohnReznick LLP.
The news has caused a precipitous decline in the price of ADMA Biologics stock. During trading on October 10, 2024, the price of ADMA Biologics stock declined more than 20%.
If you invested in ADMA Biologics you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Submit your information by visiting:
Why Bleichmar Fonti & Auld LLP?
Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs’ Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors (pending court approval), as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
Attorney advertising. Past results do not guarantee future outcomes.

Tags

Frequently Asked Questions

What is the reason for ADMA Biologics’s stock decline?

ADMA Biologics's stock dropped over 20% following the unexpected resignation of its auditor.

Who is investigating ADMA Biologics?

Bleichmar Fonti & Auld LLP is investigating ADMA Biologics for potential securities law violations.

What does Bleichmar Fonti & Auld LLP specialize in?

The firm specializes in representing plaintiffs in securities class actions and shareholder litigation.

Are there legal options for ADMA Biologics investors?

Yes, investors may have legal options and can submit their information to the firm.

Is there a cost for representation by Bleichmar Fonti & Auld LLP?

No, representation is on a contingency fee basis, with no cost to shareholders.

Last updated: Oct 31, 2024